Overview

PAI aims to commercialise biopharmaceutical products derived from PAI-2, a protein that occurs naturally in human tissue, for topical application to the skin to treat wounds and dermatological diseases. The major shareholder in PAI is Human Therapeutics Pty Ltd (holding about 63%), which is in turn controlled by Human Therapeutics Ltd, a Bermuda registered company owned by a consortium of investors including The Gemini Enterprise Market Fund Ltd and American Life Sciences Inc., entities associated with PAI director Chris Bregenhoj.

InvestSMART Publishing Pty Ltd holds Australian Financial Securities Licence (AFSL) 282288.
The content of this website is general in nature and does not take the personal situation of any user of this website into consideration.
A user of this website should seek financial advice specific to that user’s situation before making any financial decision.
Past performance of any security or financial product is not a reliable indicator of future performance. InvestSMART Publishing Pty Ltd
encourages users of this website to view investing as a long-term pursuit.